Skip to main content
Login
Contact
Subscribe
Search form
Search
The Daily Press
Home
Forms
News
Sports
Classifieds
Place a Classified Ad
Classified Display Ads
Obituaries
Entertainment
Special Sections
Talking About...
Photos
Videos
Games
Community Links
St. Mary's Chamber
Elk County Sheriff
St. Mary's Area School District
Elk County Catholic School System
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Gilead Sciences
(NQ:
GILD
)
68.48
USD
-0.36 (-0.52%)
Official Closing Price
/ Updated:
6:27 PM EDT, Jun 25, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
6,293,200
Open
68.75
Bid (Size)
68.11 (1)
Ask (Size)
68.59 (5)
Prev. Close
68.84
Today's Range
68.12 - 69.98
52wk Range
60.32 - 79.61
Shares Outstanding
1,300,260,832
Dividend Yield
3.26%
Performance
YTD
+7.94%
+7.94%
1 Month
+7.05%
+7.05%
3 Month
+6.60%
+6.60%
6 Month
+8.32%
+8.32%
1 Year
-3.74%
-3.74%
Top News
More News
Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies
June 24, 2019
Gilead Sciences, Inc. (NASDAQ: GILD) and Carna Biosciences Inc. (JASDAQ: 4572) today announced that the companies have entered into a research and development collaboration to develop and commercialize...
Read More
from
Business Wire News Releases
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
June 19, 2019
Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets
Read More
from
GlobeNewswire News Releases
More News
Read More
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
June 19, 2019
from
Business Wire News Releases
Researchers Rely on Evolving Technology to aid in the Fight Against Disease
June 13, 2019
from
PR Newswire
Notable Thursday Option Activity: GILD, ABT, DAN
June 20, 2019
category
Stocks
from
Market News Video
This would be the worst-case scenario for health companies, according UBS
June 19, 2019
category
AMGN
,
General
,
Pharmaceuticals
, and 17 more.
from
MarketWatch
3 Drugs Under FDA Review With Blockbuster Potential
June 20, 2019
category
GILD
,
CELG
,
REGN
, and 6 more.
from
Motley Fool
Biotech Stocks Heat Up, Driving ETF Gains
June 19, 2019
category
IBB
,
GILD
,
REGN
, and 11 more.
from
ETF Trends
CORRECTED-UPDATE 1-Uganda clears three experimental Ebola treatments, watches for spread
June 18, 2019
category
companyNews
from
Reuters: Company News
UPDATE 1-Uganda clears three experimental Ebola treatments, watches for spread
June 18, 2019
category
companyNews
from
Reuters: Company News
Notable ETF Outflow Detected - IBB, GILD, BIIB, VRTX
June 17, 2019
category
ETFs
from
ETF Channel
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
